comments and responses - Diabetes Care - American Diabetes

0 downloads 0 Views 30KB Size Report
Acknowledgments— D.P.M. has given talks sponsored by MSD, the manufacturer of ... Curr Med Res Opin 2009;25:2571–. 2576. 3. Gazi IF, Daskalopoulou SS, ...
O N L I N E

L E T T E R S

COMMENTS AND RESPONSES Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized DoubleBlind Clinical Trial Comment on Ruggenenti et al.

R

uggenenti et al. (1) report the effect of adding ezetimibe to simvastatin in patients with type 2 diabetes. Some additional comments could be of interest. The serum HDL cholesterol was significantly lower after adding ezetimibe

e132

compared with simvastatin monotherapy. However, the LDL-to-HDL cholesterol ratio improved (from 2.06 to 1.47 by our calculations). Was this difference significant? Ezetimibe decreased serum creatinine levels in patients (n ⫽ 742 and 108) (2–3) with baseline values at the “high end” of the reference range. Some of these patients had type 2 diabetes. Thus, Ruggenenti et al. could assess the effect of ezetimibe on renal function in this subgroup of their patients. MARIA SARIGIANNI, MD NIKI KATSIKI, MD DIMITRI P. MIKHAILIDIS, MD From the Department of Clinical Biochemistry, Vascular Disease Prevention Clinics, Royal Free Hospital Campus, University College London Medical School, University College London, London, U.K. Corresponding author: Dimitri P. Mikhailidis, [email protected]. DOI: 10.2337/dc10-1250 © 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http:// creativecommons.org/licenses/by-nc-nd/3.0/ for details.

DIABETES CARE, VOLUME 33, NUMBER 10, OCTOBER 2010

Acknowledgments — D.P.M. has given talks sponsored by MSD, the manufacturer of EZETROL (ezetimibe). He is on the advisory board for TREDAPTIVE (nicotinic acid ⫹ laropiprant) also manufactured by MSD.

● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●

References 1. Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, Remuzzi G, for the Ezetimibe and Simvastatin in dyslipidemia of Diabetes (ESD) Study Group. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 2010;33:1954 –1956 2. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP. Clinical experience with ezetimibe/ simvastatin in a Mediterranean population. Curr Med Res Opin 2009;25:2571– 2576 3. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183–2192

care.diabetesjournals.org